316 related articles for article (PubMed ID: 19325462)
1. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
Muto Y; Suzuki K; Iida H; Sakakibara S; Kato E; Itoh F; Kakui N; Ishii H
Crit Care Med; 2009 May; 37(5):1744-9. PubMed ID: 19325462
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
Suzuki K; Muto Y; Fushihara K; Kanemoto K; Iida H; Sato E; Kikuchi C; Matsushima T; Kato E; Nomoto M; Yoshioka S; Ishii H
J Pharmacol Exp Ther; 2004 May; 309(2):607-15. PubMed ID: 14762098
[TBL] [Abstract][Full Text] [Related]
3. Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis.
Sheehan M; Wong HR; Hake PW; Zingarelli B
Crit Care Med; 2003 Sep; 31(9):2263-70. PubMed ID: 14501955
[TBL] [Abstract][Full Text] [Related]
4. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
Ravindranath TM; Goto M; Iqbal O; Florian-Kujawski M; Hoppensteadt D; Hammadeh R; Sayeed MM; Fareed J
Clin Appl Thromb Hemost; 2007 Oct; 13(4):362-8. PubMed ID: 17911187
[TBL] [Abstract][Full Text] [Related]
5. EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis.
Muto Y; Suzuki K; Iida H; Ishii H
Nephron Exp Nephrol; 2007; 106(4):e113-21. PubMed ID: 17622739
[TBL] [Abstract][Full Text] [Related]
6. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
7. Curcumin attenuates the organ dysfunction caused by endotoxemia in the rat.
Memis D; Hekimoglu S; Sezer A; Altaner S; Sut N; Usta U
Nutrition; 2008; 24(11-12):1133-8. PubMed ID: 18752929
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia.
Gierer P; Hoffmann JN; Mahr F; Menger MD; Mittlmeier T; Gradl G; Vollmar B
Crit Care Med; 2007 Aug; 35(8):1966-71. PubMed ID: 17568327
[TBL] [Abstract][Full Text] [Related]
9. Melatonin protects against oxidative organ injury in a rat model of sepsis.
Sener G; Toklu H; Kapucu C; Ercan F; Erkanli G; Kaçmaz A; Tilki M; Yeğen BC
Surg Today; 2005; 35(1):52-9. PubMed ID: 15622465
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats.
Chen CH; Lee RP; Wu WT; Liao KW; Hsu N; Hsu BG
Resuscitation; 2007 Jul; 74(1):166-74. PubMed ID: 17353078
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
12. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
[TBL] [Abstract][Full Text] [Related]
13. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models.
Hagiwara S; Iwasaka H; Matumoto S; Hidaka S; Noguchi T
Crit Care Med; 2009 Feb; 37(2):626-33. PubMed ID: 19114890
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of hypertonic saline on peritonitis-induced septic shock with multiple organ dysfunction syndrome in rats.
Shih CC; Chen SJ; Chen A; Wu JY; Liaw WJ; Wu CC
Crit Care Med; 2008 Jun; 36(6):1864-72. PubMed ID: 18496380
[TBL] [Abstract][Full Text] [Related]
15. Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia--effects of selective inducible nitric oxide synthase inhibition.
Matejovic M; Krouzecky A; Radej J; Rokyta R; Kralova H; Radermacher P; Novak I
Thromb Haemost; 2007 Feb; 97(2):304-9. PubMed ID: 17264961
[TBL] [Abstract][Full Text] [Related]
16. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
Bouma BN; Mosnier LO
Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia.
Collin M; Murch O; Thiemermann C
Crit Care Med; 2006 Apr; 34(4):1131-8. PubMed ID: 16484917
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
